Cardiol Therapeutics Inc.

Market Cap: 61M
Purpose Raise Awareness, Open Market Buying

Sector: Healthcare
  • Experienced leadership team with extensive expertise in developing therapeutics for inflammatory heart diseases. Comprehensive intellectual property portfolio with a strong financial position to support research and clinical development programs into 2026.
  • Oral cannabidiol formulation, CardiolRx™, initiated clinical programs in two underserved heart diseases: (i) a Phase II multi-national trial in acute myocarditis; and (ii) a Phase II multi-center open-label pilot study in recurrent pericarditis. Cardiol intends to seek Orphan Drug Designation for CardiolRx™ for recurrent pericarditis and acute myocarditis.
  • Advance development of a subcutaneously administered formulation intended for use in heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.